Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.
Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.
Antibody discovery research paves the way for new therapeutics. The search for the right antibody for a specific therapeutic application necessitates several iterations of antibody production and ...
In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...
A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...
You don't want to miss this! To permanently access this eBook for free, fill out the short form below. Developing robust, reproducible antibody pair-based immunoassays is critical for guiding drug ...
Hosted on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Patients who depend on antibody drugs often spend long hours in infusion centers. These medicines are vital for treating many cancers, autoimmune disorders and infectious diseases, but current ...
DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback